AVBPNasdaqPharmaceutical PreparationsFiscal year ends December 31
ArriVent BioPharma, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$17.94+1.28 (+7.68%)
Close on Oct 19, 2026
- Market cap
- $854.07M
- P/E (TTM)
- –
- Dividend yield
- –
Community
Notes and questions about ArriVent BioPharma from other investors
No posts about AVBP yet
Discussion opens with sign-in. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.